USPTO Grants Patent for Benzothiazole Compound for Parkinson's and Restless Leg Syndrome
Summary
The USPTO has granted a patent (US12583829B2) to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. for a salt of a benzothiazole compound and its crystal form. The patent covers the use of this compound in the preparation of drugs for treating Parkinson's disease and restless leg syndrome.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12583829B2 for a benzothiazole compound salt, its crystal form, and its use in treating Parkinson's disease and restless leg syndrome. The patent, assigned to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., specifically covers pamoate and palmitate salts of the compound represented by formula I.
This patent grant signifies a new intellectual property right for the assignee, potentially impacting future drug development and market exclusivity for treatments related to these neurological conditions. While this is a patent grant and not a regulatory rule, it is relevant for pharmaceutical companies operating in the therapeutic areas of Parkinson's disease and restless leg syndrome, as it may affect their research, development, and commercialization strategies.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Salt of benzothiazole compound, and crystal form and use thereof
Grant US12583829B2 Kind: B2 Mar 24, 2026
Assignee
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Inventors
Long Li, Shidong Yi, Tianming Wang, Pingyun Chen, Chengxi Yang, Jingyi Wang
Abstract
Provided in the present invention are a salt of a benzothiazole compound as represented by formula I and a crystal form and the use thereof. The salt is selected from pamoate and palmitate. Further provided is the use of the salt of the compound of formula I and the crystal form thereof in the preparation of a drug for treating Parkinson's disease and restless leg syndrome.
CPC Classifications
C97D 277/82 A61K 31/428 A61P 25/16 C07D 277/82
Filing Date
2021-11-09
Application No.
18027246
Claims
28
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.